Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06429787 · ClinicalTrials.gov registry record
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
A clinical trial of Vitamin K-Dependent Coagulation Defect and Significant Bleeding Risk, sponsored by Octapharma.
- Recruiting
- Registry status
- 3,574
- Enrollment target
- 1
- Study location
NCT06429787 is a study of Vitamin K-Dependent Coagulation Defect and Significant Bleeding Risk that is actively recruiting participants, run by Octapharma. The registered enrollment target is 3,574 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06429787, a study of Vitamin K-Dependent Coagulation Defect and Significant Bleeding Risk, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- 3,574 participants
- Enrollment target
- 1
- Study location
Study Summary
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Conditions Studied
Interventions
- DRUG Balfaxar
- DRUG Kcentra
Study Locations (1)
Massachusetts
- Octapharma Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,574 participants |
| Start Date | 2025-02-14 |
| Est. Completion | 2032-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06429787
The ClinicalTrials.gov registry entry for NCT06429787 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,574 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Vitamin K-Dependent Coagulation Defect appearing as the primary indexed condition, and to 2 interventions - of which Balfaxar is the first listed.
NCT06429787 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06429787 about?
NCT06429787 is a clinical study titled "Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure". Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
What is the current status of trial NCT06429787?
This trial is currently recruiting. The enrollment target is 3,574 participants. The study started on 2025-02-14. Estimated completion is 2032-06-30.
What conditions does trial NCT06429787 study?
This clinical trial studies the following conditions: Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk.
What interventions are being tested in trial NCT06429787?
The interventions under investigation include: Balfaxar (DRUG), Kcentra (DRUG).
Who is sponsoring clinical trial NCT06429787?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06429787 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Vitamin K-Dependent Coagulation Defect
All registered trials for this condition
Significant Bleeding Risk
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.